College Stock: Penny Stock News

The recent findings of a study published in the New England Journal of Medicine indicate that the use of two of more embryos increases the likelihood of multiple birth pregnancy. Health News reports that the implantation of multiple embryos in IVF procedures used to be thought of as beneficial because it resulted in conception more often.

The Dean believes that these results offer little new information, unless the findings are made relevant by an infertility treatment, such as $IVOB’s INVO procedure, which has already taken such facts into consideration.

The Dean thinks that the earlier belief of more embryos, fewer tries and supposed success has made sense for infertile couples because of the high cost of conventional IVF procedures. However, The Dean and the CollegeStock Community know that the transfer of multiple embryos can have negative repercussions for the mother and the child.

The article suggests that medical findings and improvements in IVF procedures have resulted in the success of infertility treatments NOT the transfer of more embryos per cycle. In fact, the results of this study show that women who receive multiple embryos during IVF were more than 12 times as likely to have multiple birth pregnancies. But, The Dean believes that many doctors and infertile couples already knew this—it could just come down to a matter of what’s cost-effective for the couple.

The Dean highlighted the many downsides of multiple birth pregnancies when the topic received a lot of attention from The New York Times. Through this, we learned that the use of multiple embryos in IVF procedures can cause potentially dangerous health problems for the expecting mother (e.g. gestational diabetes, bleeding, pre-eclampsia) and the child (e.g. birth defects, cerebral palsy, developmental delays, and death).

The article suggests that many couples agree to have multiple embryos transplanted because they feel the chance of success is greater. The Dean feels that couples accept these risks and their associated costs because there are only so many options currently available for them.

But, with $IVOB’s INVO procedure gaining popularity in different parts of the world, The Dean believes that millions of infertile couples could soon have another option, which appears to be less expensive and less likely to result in multiple birth pregnancies.

The Dean believes $IVOB is getting closer to making this possible because $IVOB President and Chief Scientific Officer Dr. Claude Ranoux is attending the Procrearte Infertility Network Meeting in Buenos Aires, Argentina and $IVOB CEO Kathleen Karloff will be at the annual meeting of the Middle East Fertility Society in Egypt this week.

With 150 million infertile couples throughout the world, The Dean feels there is both a need and demand for $IVOB’s infertility treatment and this week could be another big step for The Dean’s Billion Dollar Baby.